Updates on Phase 1b TRIMM-2 Study Results of Teclistamab Plus Daratumumab in RRMM Patients (https://www.myeloma.org/videos/updates-phase-1b-trimm-2-study-results-teclistamab-plus-daratumumab-rrmm-patients)
Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022
Dr. Paula Rodríguez-Otero Provides Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab in RRMM Patients
Abstract Title:
Teclistamab in Combination with Daratumumab, a Novel, Immunotherapy-based Approach for the Treatment of Relapsed/Refractory Multiple Myeloma: Updated Phase 1b Results
What is the purpose of this trial?
Teclistamab (JNJ-64007957) is a B-cell maturation antigen (BCMA) × CD3 T-cell redirecting bispecific antibody currently under investigation in patients with relapsed/refractory multiple myeloma (RRMM). Daratumumab (Dara) is a CD38-targeting monoclonal antibody with direct on-tumor and immunomodulatory mechanisms of action. The preliminary results from the phase 1b multicohort TRIMM-2 study showed tolerable safety with no overlapping toxicities, and encouraging efficacy, supporting the combination of teclistamab with daratumumab for the treatment of RRMM.
Updated results from the TRIMM-2 study with additional patients and longer follow-up are reported here.
In this video:
Dr. Paula Rodríguez-Otero (University of Navarra—Pamplona, Spain) discusses updated Phase 1b TRIMM-2 results of Teclistamab Plus Dara in relapsed/refractory multiple myeloma (RRMM) patients.
Conclusion:
Teclistamab, in combination with daratumumab, is a novel immunotherapy approach that may yield improved clinical efficacy in heavily pretreated patients with RRMM.
Doctor Bio:
Dr. Paula Rodríguez-Otero MD, PhD, is a Specialist in Hematology and Hemotherapy; Medical Coordinator of the Central Unit for Clinical Trials at CIMA Universidad de Navarra and Clinica Universidad de Navarra in Pamplona, Spain.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology